Melanoma News and Research

Latest Melanoma News and Research

New approaches to treating lung cancer patients in New Mexico

This year, more than 158,000 Americans are expected to die from lung cancer. That's a staggering number: it's more than all the deaths expected from breast, prostate, colon, rectum, bladder and skin cancers combined.

26 Oct 2015

New joint initiative to explore clinical interpretation of molecular tests for cancers

A new conference helping doctors navigate one of the most important scientific questions faced by the cancer community could help improve survival rates for patients.

23 Oct 2015

Amgen's IMLYGIC receives positive opinion from CHMP for treatment of melanoma

Amgen today announced that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, has adopted a positive opinion recommending that IMLYGIC (talimogene laherparepvec) be granted approval for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.

23 Oct 2015

Patrolling monocytes may play anti-cancer role in the lung

One goal of immunotherapy is to rally a patient's often over-burdened immune cells to effectively attack a tumor. Among foot soldiers on the immune front line is a subpopulation of white blood cells called "patrolling monocytes," whose job is to cruise the bloodstream, cart off cellular debris, and block invasion of a less benign population of inflammatory cells.

23 Oct 2015

Michelson Diagnostics’ VivoSight OCT scanner provides accurate diagnosis of early-stage BCC, reduces skin biopsies by 36%

Michelson Diagnostics, a medical device company focused on applications of multi-beam Optical Coherence Tomography technology, today announces data showing that use of its VivoSight OCT scanner significantly improves diagnosis of basal-cell carcinoma at an earlier stage and reduces diagnostic biopsies by 36%.

22 Oct 2015

Sequenom enters into clinical collaboration with CU School of Medicine

Sequenom, Inc., a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that it has entered into a clinical collaboration with the University of Colorado Denver, School of Medicine.

19 Oct 2015

TGen researchers join international scientists in discovering how malaria protein could some day help stop cancer

Researchers at the Translational Genomics Research Institute joined an international team of scientists in discovering how a protein from malaria could some day help stop cancer.

19 Oct 2015

Special CD4+ T cells appear to inhibit cancer growth, enhance tumor-killing powers of other immune cells

The key to immune-based cancer therapies lies in the ability to exploit some weakness within the tumor and its environment or to elude cancer's offenses. Writing in the journal Scientific Reports, researchers led by a group from the Roswell Park Cancer Institute Center for Immunotherapy have shared new insights about a subset of T cells that appear to do both those things, inhibiting cancer growth at the same time that they enhance the tumor-killing powers of other immune cells.

19 Oct 2015

RXI-109 use after scar revision surgery has beneficial effect on suppression of hypertrophic scarring

RXi Pharmaceuticals Corporation, a biotechnology company that owns a broad intellectual property portfolio including a unique self-delivering RNAi platform, today announced that results from a blinded panel and an Investigator review show that incision sites treated with RXI-109 after scar revision surgery achieved better scores as compared to control incision sites in the same subjects, three months post scar revision surgery.

19 Oct 2015

New research raises hope for novel cancer immunotherapy

New research by Dana-Farber Cancer Institute scientists raises the prospect of cancer therapy that works by converting a tumor's best friends in the immune system into its gravest enemies.

16 Oct 2015

OHSU designs new iPhone app to advance melanoma research

Oregon Health & Science University today released an iPhone app designed to advance melanoma research by giving users the ability to accurately measure and monitor moles, and contribute photos of how their potential trouble spots evolve over time.

16 Oct 2015

Novel ligand peptide-mimic inhibits abnormal overgrowth of blood vessels, may lead to new anti-cancer drugs

An international research team led by scientists at the University of New Mexico Cancer Center discovered and developed a novel ligand peptide-mimic that inhibits abnormal overgrowth of blood vessels in retinal diseases and tumors. The discovery could lead to new drugs that keep cancers from growing. The team published a paper in the journal Science Translational Medicine.

15 Oct 2015

OncoSec reports net loss of $6.5 million for fourth quarter of fiscal 2015

OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the fourth quarter and fiscal year ended July 31, 2015.

15 Oct 2015

CU Cancer Center study reports 'robust antitumor activity' of TAK-733 drug in mouse models of colorectal cancer

A University of Colorado Cancer Center study recently published online ahead of print in the journal Oncotarget reports "robust antitumor activity" of the drug TAK-733 in cells and mouse models of colorectal cancer.

14 Oct 2015

Researchers find significant link between breast cancer and nutrition, explore new preventative treatment

Researchers at Sydney’s Centenary Institute are working on a new treatment aimed at “starving” breast cancer cells, following the discovery of a significant link between breast cancer and nutrition.

14 Oct 2015

Lilly, ImaginAb partner to study potential novel T-cell-based immuno-oncology therapies

Eli Lilly and Company and ImaginAb Inc. are pleased to announce a preclinical research collaboration to study potential novel T-cell-based immuno-oncology therapies.

13 Oct 2015

Can-Fite's CF102 granted Orphan Drug Designation by EMA for treatment of hepatocellular carcinoma

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the Company's oncology drug candidate, CF102, has been granted Orphan Drug Designation by the European Medicines Agency (EMA) for the indication of hepatocellular carcinoma (HCC), the most common form of liver cancer.

12 Oct 2015

Discovery may help scientists to better predict how quickly HIV virus returns after patients stop treatment

Scientists are now better able to predict how quickly the HIV virus will return after individuals stop treatment following a discovery by researchers at UNSW Australia and the University of Oxford.

12 Oct 2015

Study looks at survival benefits of surgical resection for melanoma patients with abdominal metastases

Patients with metastatic melanoma who undergo surgery to remove lesions that have spread into the abdomen live more than twice as long as those treated with drug therapy alone, according to novel new research by a North Shore-LIJ Health System cancer surgeon.

12 Oct 2015

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.

9 Oct 2015

Melanoma News and Research

Latest Melanoma News and Research

New approaches to treating lung cancer patients in New Mexico

New joint initiative to explore clinical interpretation of molecular tests for cancers

Amgen's IMLYGIC receives positive opinion from CHMP for treatment of melanoma

Patrolling monocytes may play anti-cancer role in the lung

Michelson Diagnostics’ VivoSight OCT scanner provides accurate diagnosis of early-stage BCC, reduces skin biopsies by 36%

Sequenom enters into clinical collaboration with CU School of Medicine

TGen researchers join international scientists in discovering how malaria protein could some day help stop cancer

Special CD4+ T cells appear to inhibit cancer growth, enhance tumor-killing powers of other immune cells

RXI-109 use after scar revision surgery has beneficial effect on suppression of hypertrophic scarring

New research raises hope for novel cancer immunotherapy

OHSU designs new iPhone app to advance melanoma research

Novel ligand peptide-mimic inhibits abnormal overgrowth of blood vessels, may lead to new anti-cancer drugs

OncoSec reports net loss of $6.5 million for fourth quarter of fiscal 2015

CU Cancer Center study reports 'robust antitumor activity' of TAK-733 drug in mouse models of colorectal cancer

Researchers find significant link between breast cancer and nutrition, explore new preventative treatment

Lilly, ImaginAb partner to study potential novel T-cell-based immuno-oncology therapies

Can-Fite's CF102 granted Orphan Drug Designation by EMA for treatment of hepatocellular carcinoma

Discovery may help scientists to better predict how quickly HIV virus returns after patients stop treatment

Study looks at survival benefits of surgical resection for melanoma patients with abdominal metastases

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Melanoma News and Research

Latest Melanoma News and Research

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Newsletters you may be interested in